Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Denali Therapeutics Inc. (DNLI) vs Xenon Pharmaceuticals Inc. (XENE)

Denali Therapeutics Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Xenon Pharmaceuticals Inc. is the larger, with a market value of $3.7B against $3.4B — 1.1× the size. Denali Therapeutics Inc. grew revenue faster over the last twelve months: 194.7% against −8.15%. Xenon Pharmaceuticals Inc. has the higher net margin (0.00% vs −171.1%) and the higher return on invested capital (−88.5% vs −260.5%). Across the 18 metrics below, Xenon Pharmaceuticals Inc. leads on 13 and Denali Therapeutics Inc. on 5.

Valuation

Metric DNLI XENE Biotechnology median
P/E n/m n/m 7.88
P/S 12.77 217.29 11.47
P/B 4.57 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 10.42 162.98 10.73
Earnings yield (13.93%) (12.83%) (28.84%)
Free cash flow yield (11.45%) (9.20%) (23.03%)

Profitability

Metric DNLI XENE Biotechnology median
Gross margin 99.97% 28.40% 65.16%
Operating margin (181.51%) 0.00% 0.00%
Net margin (171.06%) 0.00% 0.00%
Free cash flow margin (146.31%) 0.00% 0.00%
Return on equity (54.93%) (43.62%) (57.72%)
Return on assets (44.01%) (41.54%) (49.22%)
Return on invested capital (260.54%) (88.54%) 0.00%

Growth

Metric DNLI XENE Biotechnology median
Revenue growth (TTM) 194.68% (8.15%) 5.64%
EPS growth (last fiscal year) (15.56%) (44.85%) —
Revenue growth, 5-year CAGR 20.67% 89.00% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNLI XENE Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 8.37 21.02 4.73
Net debt to EBITDA 1.56 1.48 0.96

Dividend

Metric DNLI XENE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DNLI XENE Biotechnology median
Market cap 3.36b 3.73b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack